Indirect hyperbilirubinemia with indinavir.

Satija, P; Parikh, Falguni; Aggarwal, V; Sharma, B; Hakim, Avi; Pai-Dhungat, J V

Satija, P; Parikh, Falguni; Aggarwal, V; Sharma, B; Hakim, Avi; Pai-Dhungat, J V.

Article in English | IMSEAR | ID: sea-95546

ABSTRACT

ABSTRACT

Indinavir is a protease inhibitor used in the treatment of HIV infected individuals and as post-exposure prophylaxis. Indinavir is associated with various adverse effects including gastrointestinal, a lipodystrophy syndrome and nephrolithiasis. We describe indirect hyperbilirubinemia as an adverse effect of indinavir in a person on post-exposure prophylaxis (PEP).

Subject(s)

Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections/prevention & control; HIV Protease Inhibitors/adverse effects; Humans; Hyperbilirubinemia/chemically induced; India; Indinavir/adverse effects; Lamivudine/therapeutic use; Liver Function Tests; Prognosis; Risk Assessment; Severity of Illness Index; Zidovudine/therapeutic use

Fulltext

XML

Search on Google

Full text: Available Index: IMSEAR (South-East Asia) Main subject: Prognosis / Severity of Illness Index / Female / Humans / Zidovudine / HIV Infections / HIV Protease Inhibitors / Risk Assessment / Indinavir / Lamivudine Type of study: Etiology study / Prognostic study / Risk factors Country/Region as subject: Asia Language: English Year: 2002 Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google